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Abstract
Background: Tetherin (also known as BST-2, CD317, and HM1.24) is an interferon- induced protein that blocks the
release of a variety of enveloped viruses, such as retroviruses, filoviruses and herpesviruses. However, the
relationship between tetherin and foamy viruses has not been clearly demonstrated.
Results: In this study, we found that tetherin of human, simian, bovine or canine origin inhibits the production of
infectious prototypic foamy virus (PFV). The inhibition of PFV by human tetherin is counteracted by human
immunodeficiency virus type 1 (HIV-1) Vpu. Furthermore, we generated human tetherin transmembrane domain
deletion mutant (delTM), glycosyl phosphatidylinositol (GPI) anchor deletion mutant (delGPI), and dimerization and
glycosylation deficient mutants. Compared with wild type tetherin, the delTM and delGPI mutants only moderately
inhibited PFV production. In contrast, the dimerization and glycosylation deficient mutants inhibit PFV production
as efficiently as the wild type tetherin.
Conclusions: These results demonstrate that tetherin inhibits the release and infectivity of PFV, and this inhibition
is antagonized by HIV-1 Vpu. Both the transmembrane domain and the GPI anchor of tetherin are important for
the inhibition of PFV, whereas the dimerization and the glycosylation of tetherin are dispensable.
Background
Retrovirus infection causes either acute or chronic dis-
eases. To counteract, host cells have a variety of restric-
tion factors to inhibit or block retrovirus infection.
These include APOBECs (apolipoprotein B mRNA-edit-
ing catalytic polypeptides) [1,2], TRIM5a (tripartite
motif protein 5-alpha) [3,4], TRIM28 (tripartite motif-
containing 28) [5,6], ZAP (zinc-finger antiviral protein)
[7,8] and tetherin [9,10].
Tetherin (also named BST-2, CD317, and HM1.24)
has recently been described as a restriction factor in
human cells, which can block the release of many envel-
oped viruses, such as retroviruses [9], filoviruses [11-13]
and herpesviruses [14]. The expression of tetherin varies
among different cell types and can be induced by type I
interferon [9,10]. Some viruses have developed different
strategies to overcome tetherin’s restriction. Human
immunodeficiency virus type 1 (HIV-1) Vpu and K5 of
Kaposi’s sarcoma-associated herpesvirus (KSHV) cause
the degradation and cell surface downregulation of
tetherin [9,14,15]. This can be achieved by targeting
tetherin to the trans-Golgi network or to endosomes for
proteasomal or lysosomal degradation by a b-TrCP-
dependent mechanism [16-18]. HIV-2 Env and simian
immunodeficieincy virus (SIV) Nef can reduce the
expression of cell surface tetherin [19-21].
Tetherin is a 30-36 kDa type II transmembrane pro-
tein. It consists of four domains, an N-terminal cytoplas-
mic tail (CT), a single transmembrane domain (TM), an
extracellular coiled-coil domain and a C-terminal glyco-
syl phosphatidylinositol (GPI) anchor [22-25]. Tetherin
forms stable homodimers and is modified by asparagine-
linked glycosylation [24]. Tetherin of human origin con-
tains five cysteine residues. The three cysteine residues
at positions 53, 63 and 91 in the extracellular domain
are involved in disulfide bond-linked dimerization of
tetherin [22,24].
Foamy viruses, also known as spumaretroviruses, are
unconventional enveloped retroviruses that compose the
only genus in the Spumaretrovirinae subfamily of Retro-
viridae. Foamy viruses replication has similarities to
both hepadnaviruses and conventional retroviruses [26].
In this study, to explore the relationship between
tetherin and foamy viruses, we detected the release and
infectivity of prototypic foamy virus (PFV) after
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any medium, provided the original work is properly cited.transfecting 293T cells with tetherin and PFV infectious
clone. A series of deletions and mutations of tetherin
were constructed to demonstrate the importance of the
special structures of tetherin for its antiviral function.
Furthermore, the cDNA of tetherins from bovine and
canine origin were cloned to elucidate whether the inhi-
bition of tetherin to PFV is species-specific.
Materials and methods
Plasmids
PFV full-length infectious clone pcPFV was kindly pro-
vided by Maxine L. Linial [27]. Flag-HuTHN and Flag-
AgmTHN was subcloned from pcDNA3.1-HuTHN and
pcDNA3.1-AgmTHN into pCMV-Tag2B (Stratagene)
vector. The BovTHN cDNA and CanTHN cDNA were
amplified by reverse transcription (RT)-PCR from RNA
samples that were extracted from fetal bovine lung (FBL)
cells and a fetal canine thymus cell line (Cf2Th), followed
by insertion into pCMV-Tag2B vector. The Flag-HuTHN
delCT (20-180 aa), Flag-HuTHN delTM (47-180 aa),
Flag-HuTHN delGPI (1-161 aa), Flag-AgmTHN delCT
(26-182 aa), Flag-AgmTHN delTM (50-182 aa) and Flag-
AgmTHN delGPI (1-159 aa) were constructed by insert-
ing individual PCR fragment into pCMV-Tag2B vector.
The human tetherin mutant C53/63/91A was provided
by Klaus Strebel. HuTHN C53/63/91A was subcloned
into pCMV-Tag2B vector. HuTHN mutants with
cysteine or asparagine to alanine substitutions, C53A,
C63A, C91A, C53/63A, C63/91A, C53/91A, N65/92A
and C3A/N2A, were generated from Flag-HuTHN and
Flag-HuTHN C53/63/91A, using a QuikChange site-
directed mutagenesis kit (Stratagene) (Table 1). All the
new constructs were verified by sequencing.
Cells, viruses, and reagents
293T, BHK-21, and PFV indicator cell line (PFVL) cells
were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum, 50 IU/ml
penicillin, and 50 μg/ml streptomycin at 37°C in humi-
dified air with 5% CO2. The indicator cell line PFVL
was created by transfecting BHK-21 with reporter plas-
mid containing the firefly luciferase gene driven by a
PFV long terminal repeat promoter. At 48 h post-trans-
fection, the medium was changed with the addition of
600 μg/ml neomycin (G418, Promega) for additional
three weeks. The cells were replaced with fresh medium
every three days. To obtain positive stable monoclones,
G418-resistant cells were isolated further by plating
them at a limiting dilution on to 96-well plates. 293T
cells were transfected with pcPFV proviruses along with
either wild type tetherin or mutants. Cell lysates and
viral supernatants were collected at between 44 and 48
h posttransfection. Transient transfection was performed
using 1 mg/ml polyethyleneimine (PEI) (Sigma) as pre-
viously described [28].
Western blotting
Cells were washed twice with PBS, suspended in PBS, and
mixed with an equal volume of sample buffer (4% sodium
dodecyl sulfate, 125 mM Tris-HCl, pH 6.8, 10% 2-mer-
captoethanol, 10% glycerol, and 0.002% bromophenol
blue). For analysis of cysteine mutants under non-redu-
cing conditions, cells were suspended in PBS and mixed
with an equal volume of sample buffer that did not con-
tain 2-mercaptoethanol. Proteins were solubilized by
boiling for 20 min at 95°C. Western blot analyses were
performed using anti-Gag polyclonal rabbit serum (pro-
vided by Maxine L. Linial) at a 1:5,000 dilution. The com-
mercially available anti-Flag monoclonal antibody
(Stratagene) was used at a 1:5,000 dilution. Anti-b-actin
monoclonal mouse antibody (Sigma-Aldrich) was used at
a 1:2,000 dilution as a loading control. After hybridizing
the membrane with secondary goat anti-rabbit antibody
a n dg o a ta n t i - m o u s ea n t i b o d ya ta1 : 1 0 , 0 0 0d i l u t i o n ,
enhanced chemiluminescence reagents (Millipore) were
used for signal detection with X-ray film.
Table 1 Descriptions of used plasmids
Name Descriptions
Flag-HuTHN, Flag-AgmTHN, Flag-BovTHN, Flag-CanTHN Human, African green monkey, bovine and canine tetherin expression plasmids
Flag-HuTHN delCT, Human tetherin 20-180 aa expression plasmid
Flag-HuTHN delTM Human tetherin 47-180 aa expression plasmid
Flag-HuTHN delGPI Human tetherin 1-161 aa expression plasmid
Flag-AgmTHN delCT African green monkey tetherin 26-182 aa expression plasmid
Flag-AgmTHN delTM African green monkey tetherin 50-182 aa expression plasmid
Flag-AgmTHN delGPI African green monkey tetherin 1-159 aa expression plasmid
HuTHN C53A, HuTHN C63A, HuTHN C91A Human tetherin single cysteine mutated to alanine
HuTHN C53/91A, HuTHN C53/63A, HuTHN C63/91A Human tetherin two of the three cysteines mutated to alanines
HuTHN C53/63/91A Human tetherin all three cysteines mutated to alanines
HuTHN N2A Human tetherin two asparagines at 65 and 92 mutated to alanines
HuTHN C3A/N2A Human tetherin all three cysteines and two asparagines mutated to alanines
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tants of transfected cells, viral supernatants were col-
lected, centrifuged at 2,000 rpm for 10 min to remove
cell debris, and then pelleted through a 20% sucrose
cushion for 2 h at 24,000 rpm and 4°C (Beckman). Viral
pellets were resuspended in PBS and mixed with SDS
sample buffer prior to loading onto a 10% protein gel.
After proteins were separated by electrophoresis, they
were transferred to nitrocellulose membranes (GE). The
membranes were then blocked using Odyssey blocking
buffer (LI-COR Biosciences) and incubated with anti-
Gag polyclonal rabbit serum. Odyssey secondary antibo-
dies were added according to the manufacturer’s
instructions (goat anti-rabbit IRDye 680). Blots were
imaged using an Odyssey Infrared Imaging System (LI-
COR Biosciences). Scan resolution of the instrument
ranges from 21 to 339 μm, and in this study blots were
imaged at 169 μm. Quantification was performed on
single channels with the analysis software provided (LI-
COR Biosciences).
Luciferase assay
The indicator cells were plated in 96-well plates (10
4/
well) and cultured at 37°C for 18 h. Then cells were
infected with viral supernatants. After replacing the
virus stock with the maintenance medium, cells were
incubated at 37°C for 48 h. The luciferase activity was
measured by using a 96-channel chemiluminescense
measurement machine Glomax (Promega, USA). Read-
out was counts per second. The relative light unit was
determined automatically.
Viral DNA copy number assay
The viral supernatants were collected at between 44 and
48 h posttransfection, centrifuged at 2,000 rpm for 10
min to remove cell debris, and pelleted through a 20%
sucrose cushion for 2 h at 24,000 rpm and 4°C (Beck-
man). After resuspending viral pellets in PBS, viral DNA
was extracted using QIAamp UltraSens Virus Kit (QIA-
GEN). Then viral DNA was quantified by real-time PCR
using iQ SYBR green supermix (Bio-Rad). To generate a
standard curve for cycle thresholds versus copy num-
bers, the pCMVTag-Gag plasmid was serially diluted to
known concentrations. Primers for the amplification of
gag gene were 5’-AATAGCGGGCGGGGACGACA- 3’
and 5’-ATTGCCACGCACCCCAGAGC-3’.T h eD N A
copy number was calculated using Bio-Rad iCycler soft-
ware (version 3.1).
Results
Human tetherin inhibits the release of PFV
We first examined whether human tetherin inhibits PFV
release. To this end, we transfected 293T cells with the
full-length PFV DNA construct named pcPFV and a
human tetherin cDNA plasmid HuTHN. At 48 h after
transfection, the amount of virus in supernatants was
analyzed by Western blotting of Gag protein, viral DNA
copy number assay and by infecting an indicator cell
line named PFVL. PFV production and infectivity was
reduced by human tetherin in a dose dependent man-
ner, without affecting the expression of cell-associated
Gag protein (Figure 1A, B).
HIV-1 Vpu counteracts tetherin by causing downregu-
lation of cell surface tetherin [10,16,29,30]. To deter-
mine whether the antiviral activity of tetherin against
PFV is antagonized by Vpu, HIV-1 Vpu was co-
expressed with pcPFV and human tetherin. As expected,
Vpu enhanced the release of PFV in the presence of
tetherin (Figure 1C, D). Together, these data suggest
that human tetherin inhibits the release of PFV and this
inhibition is overcome by HIV-1 Vpu.
Both the transmembrane domain and the GPI anchor of
human tetherin are important for the inhibition of PFV
Tetherin was originally identified as a specific marker of
late-stage B-cell maturation and a potential target for
the immunotherapy of multiple myeloma [24,31]. It has
an N-terminal transmembrane domain (TM) and a C-
terminal GPI anchor. It associates with lipid rafts at the
cell surface and on internal membranes [22]. In order to
test whether these two domains are required for inhibi-
tion of PFV, we generated the cytoplasmic tail deletion
mutant (delCT), transmembrane domain deletion
mutant (delTM) and GPI deletion mutant (delGPI) (Fig-
ure 2A). The delCT mutant suppressed PFV production
as efficiently as the wild type tetherin; in contrast, the
delTM and the delGPI mutants only moderately inhib-
ited PFV production (Figure 2B, C). These data suggest
that the transmembrane domain and the GPI anchor of
human tetherin are important for the inhibition of PFV.
Dimerization and glycosylation of tetherin are not
essential for inhibiting PFV
Three cysteine residues C53, C63 and C91 contribute to
tetherin dimerziation by forming disulfide bonds. To
test their role in the antiviral activity of tetherin, we cre-
ated three groups of mutants. The first group includes
C53A, C63A and C91A that change each cysteine into
an alanine. The second group includes C53/63A, C63/
91A and C53/91A that change two cysteines into ala-
nines. The third group is a C53/63/91A mutant that
changes all three cysteines into alanines. We also
mutated the two glycosylation sites at N65 and N92,
and created the N65/92A mutant. Lastly, we generated
the C3A/N2A mutant that changed the three cysteines
and the two asparagines to alanines (Figure 3A). These
mutants were expressed in 293T cells and the cell
lysates were prepared in a buffer with or without b-ME.
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27-35 kDa monomer pattern under the reducing condi-
tion (+b-ME), while N65/92A and C3A/N2A reduced
the apparent molecular weight to 17-20 kDa due to the
lack of glycosylation. However, under the non-reducing
condition, all mutants, except for C53/63/91A and C3A/
N2A, formed the 60-70 kDa dimer. This result suggests
that mutation of any individual cysteine or any two of
the three cysteines in combination does not abolish
tetherin dimerization. We next tested whether these
mutants were able to inhibit PFV production. Since the
mutants were expressed at different levels when the
same amounts of plasmid DNA were transfected into
293T cells (Figure 3B), we thus adjusted the amount of
plasmid DNA used for transfection such as to achieve
similar expression levels of different mutants in order to
Figure 1 Tetherin inhibits the release of PFV. (A, B) 293T cells were transfected with PFV infectious clone pcPFV along with human tetherin
expression plasmids (HuTHN). At 44-48 h after transfection, the amount of virus in supernatants was analyzed by infecting an indicator cell line
PFVL, Western blotting (A), and viral DNA copy number assay (B). (C, D) 293T cells were transfected with pcPFV, HuTHN, and HIV-1 Vpu
expression plasmid. The virus titer in the supernatants was analyzed by infecting PFVL. The luciferase activity and viral DNA copy number were
normalized to the samples transfected with empty vectors. The cell lysates were immunoblotted with anti-Gag antibody. The same blots were
reprobed with anti- b-actin antibody and anti-FLAG antibody. The viral particles were immunoblotted with anti-Gag antibody and Odyssey goat
anti-rabbit IRDye 680. The intensity showed below the blots was performed with LI-COR analysis software.
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(data not shown). Interestingly, all mutants suppressed
PFV production efficiently (Figure 3C). Furthermore,
mutants C53/63/91A, N65/92A and C3A/N2A inhibited
PFV release in a dose dependent manner (Figure 3D-F).
These results indicate that dimerization and glycosyla-
tion are not essential for human tetherin to inhibit PFV
release.
Tetherin from simian, bovine and canine inhibit the
release of PFV
PFV productively infects various cell lines that are
derived from human, chimpanzees, monkeys, cows and
dogs. We thus wished to test whether tetherins from
these latter species could also inhibit PFV production.
We cloned the cDNA of tetherins from bovine and
canine from fetal bovine lung (FBL) cells and a fetal
canine thymus cell line (Cf2Th). Tetherins of human,
simian, bovine or canine origin displayed 59.5% identity
at the amino acid level. To measure their ability to sup-
press PFV release, pcPFV was cotransfected with cDNA
clones of human tetherin, African green monkey
tetherin, bovine tetherin, or canine tetherin into 293T
cells. The results show that all tetherins tested signifi-
cantly inhibit the release of PFV (Figure 4) and that the
inhibition effect of tetherin is dose-dependent (Figure
5A-C). Furthermore, both the TM domain and the GPI
anchor of African green monkey tetherin are important
for the inhibition of PFV (Figure 5D).
Discussion
Foamy viruses are subject to restriction by several host
factors. For example, APOBEC3G was reported to inhi-
bit PFV, simian foamy virus (SFV) and feline foamy
virus (FFV), and this restriction was counteracted by the
Bet protein [32-34]. Trim5a could also restrict PFV,
SFV, or FFV by targeting viral Gag protein [35]. In this
study, we report that tetherin inhibits the release of PFV
without affecting the expression of cell-associated Gag
protein. Tetherin has been reported to block the release
of retroviral, filoviral, arenaviral and paramyxoviral
virus-like particles (VLPs) [11,36]. Here we demonstrate
that, the production of infectious PFV is inhibited by
tetherin. HIV-1 Vpu was found to enhance the detach-
ment of infectious virions from the cell surface by
downregulating the level of tetherin at the host cell sur-
face and reducing its total cellular level [10,29]. This
effect of Vpu is not limited to HIV-1 but was shown to
rescue other viruses such as Rous sarcoma virus (RSV),
M o l o n e ym u r i n el e u k e m i av i r u s( M u L V ) ,a n dX e n o t r o -
pic murine leukemia virus related virus (XMRV), as well
as unrelated enveloped vir u s e ss u c ha sE b o l av i r u s
Figure 2 TM domain and GPI domain of human tetherin are
important for the inhibition of PFV. (A) Schematic
representations of human tethrin (HuTHN) and deletion mutants.
WT, wild type; delCT, HuTHN (20-180 aa); delTM, HuTHN (47-180 aa);
delGPI, HuTHN (1-161 aa). (B, C) pcPFV was transfected into 293T
cells together with the indicated HuTHN wild type or truncated
mutants. The amount of virus in supernatants was analyzed by
infecting PFVL (B), Western blotting (B), and viral DNA copy number
assay (C). The luciferase activity and viral DNA copy number were
normalized to the samples transfected with empty vectors (control).
The cell lysates were immunoblotted with anti-Gag antibody. The
same blots were reprobed with anti- b-actin antibody and anti-
FLAG antibody. The viral particles were immunoblotted with anti-
Gag antibody and Odyssey goat anti-rabbit IRDye 680. The intensity
showed below the blots was performed with LI-COR analysis
software.
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Page 5 of 10Figure 3 The dimerization and glycosylation of human tetherin are not essential for its antiviral activity against PFV.( A )S c h e m a t i c
representations of tetherin and various cysteine or asparagine to alanine mutants. (B) WT and mutant tetherin expressed in 293T cells were
analyzed under both reducing and non-reducing conditions by Western blotting (*, non-specific band). (C) pcPFV was transfected into 293T cells
together with the indicated human tetherin wild type or mutants. The titer of virus in supernatants was analyzed by infecting PFVL. (D-F) 293T
cells were transfected with pcPFV and indicated 10, 20, 50, 100 ng of HuTHN mutants C53/63/91A (D), N65/92A (E), or C3A/N2A (F). The titer of
virus in supernatants was analyzed by infecting the PFVL indicator cells.
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Page 6 of 10[11,13,37]. Here our results show that, vpu enhances the
release of PFV in the presence of human tetherin, and is
consistent with previous reports [11].
Tetherin is a type II transmembrane protein that has
both an N-terminal transmenbrane (TM) domain and a
C-terminal glycosyl phosphatidylinositol (GPI) anchor.
The TM domain and GPI anchor of tetherin were
reported to be essential for its antiviral function against
HIV-1 [9]. Consistent with this, the mutant delTM,
which lacks the N-terminal transmembrane domain and
is retained in the cell membrane only by its GPI anchor,
did not block PFV release effectively. Similar results
were shown for the delGPI mutant in which the GPI
anchor signal was removed. These results suggest that
N-terminal transmembrane domain and C-terminal GPI
anchor at either end of the coiled-coil domain are
important for the inhibition of PFV.
Tetherin can form stable cysteine-linked homodimers
and can be modified by N-linked glycosylation. Forma-
tion of cysteine-linked tetherin dimers was shown to be
a functional requirement for inhibition of HIV-1 release
[38,39]. However, dimerization of tetherin was not
essential for inhibiting Lassa and Marburg viruses [40].
Our results showed that neither the formation of
cysteine-linked dimer nor the asparagines-linked glyco-
sylation was required for inhibiting PFV. The mutants,
C3A (all three cysteines were mutated) that does not
form cysteine-linked dimer, and C3A/N2A (all three
cysteines and two asparagines were replaced with ala-
nines) that is unable to form homodimers and is not
modified by glycosylation, still exhibit potent antiviral
activity against PFV. These suggest that the dimerization
and glycosylation of tetherin are not important for its
antiviral activity against PFV.
Tetherins from different species have been shown to
possess different antiviral functions and have different
sensitivities to various viral countermeasures
[17,18,41-43]. HIV-1 release is inhibited by tetherins
from a wide selection of mammalian species, including
Old World monkeys, such as rhesus macaques [20,41],
African green monkeys [18,44], and Mustached monkeys
[42], as well as mice and rats [17,41]. However, tetherin
from a species of New World owl monkey (Aotus lemur-
inus griseimembra) is unable to restrict HIV-1 [43]. For
PFV, it has a wide host range and can be isolated from
saliva in infected animals. We thus cloned the bovine
and canine tetherin and demonstrated that not only
human tetherin, but also the simian, bovine and canine
tetherin could inhibit the release of PFV.
Several models have been proposed to elucidate the
possible mechanisms behind the antiviral activity of
tetherin [9,39]. Some models indicated that tetherin
Figure 4 Not only human tetherin, but also tetherins from
simian, bovine and canine inhibit the release of PFV. 293T cells
were transfected with pcPFV- along with human tetherin (HuTHN),
African green monkey tetherin (AgmTHN), bovine tetherin (BovTHN),
or canine tetherin (CanTHN). At 44-48h after transfection, the
amount of virus in cell lysates and supernatants was analyzed by
infecting PFVL (A), Western blotting (B), and viral DNA copy number
assay (C). The FLAG-tag tetherin and Gag proteins were
immunoblotted with the antibodies indicated on the left side of
each blot. The blot for b-actin was performed as an internal control.
The luciferase activity and viral DNA copy number were normalized
to the samples transfected with empty vectors (control).
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ions and the plasma membrane. Other models predicted
that tetherin might tether virions and cells through
some interactions with viral proteins or cellular proteins.
However, a completely artificial tetherin-like protein
using domains from other proteins, lacking significant
sequence homology to native tetherin, could mimic the
biological activity of native tetherin [39]. Also, immu-
noelectron microscopy performed on HIV-infected T
cells demonstrated that tetherin formed an apparent
physical link between virions and connected virions to
t h ep l a s m am e m b r a n e[ 4 5 ] .T h e s ed a t as t r o n g l ys u g g e s t
that tetherin directly tethers viral particles to cellular
membranes, and that the tethering activity does not
involve interactions with any specific cellular or viral
cofactors, signaling or other indirect mechanisms. Con-
sistent with these models, our results showed the major
structural features of tetherin, the two membrane
anchors were essential for the inhibition to PFV.
Tetherin may retain virus particles by two mechan-
isms. In one mechanism, one pair of membrane anchors
of tetherin dimer are incorporated into virus, and the
other pair still remain in cell membrane. In the other
mechanism, the two membrane anchors of one mono-
mer tetherin are embedded into virus. The anchors of
the other monomer are in cell membrane. In this latter
mechanism, the dimerization is necessary for the anti-
viral activity. In our research, the mutation which was
unable to form homodimers still could inhibit the
release of PFV effectively, the dimerization is thus not
essential for the inhibition to PFV. This observation
supports the first model.
Recently, it was demonstrated that tetherin/BST-2 not
only inhibited release of Vpu-deleted HIV-1 particles by
Figure 5 Tetherins inhibit the release of PFV in a dose-dependent manner. Both the TM domain and GPI anchor of AgmTHN are important
for the inhibition to PFV. (A-C) pcPFV was transfected into 293T cells together with the indicated 10, 20, 50, 100 ng of BovTHN (A), CanTHN (B),
or AgmTHN (C). The titer of virus in supernatants was analyzed by PFVL. (D) 293T cells were transfected with pcPFV, together with the indicated
AgmTHN wild type or truncation mutants. WT, wild type AgmTHN; delCT, AgmTHN (26-182 aa); delTM, AgmTHN (50-182 aa); delGPI, AgmTHN (1-
159 aa). The titer of virus in supernatants was analyzed by infecting PFVL.
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infectivity of the progeny virions. The latter defect was a
result of incomplete viral Gag processing and deficient
maturation of HIV-1 particles caused by tetherin [46].
In our research, the infectivity of PFV from cells trans-
fected with tetherin was also reduced significantly.
Therefore, more studies will be necessary to elucidate
how tetherin abrogates the infectivity of PFV.
Conclusions
This study demonstrate that for foamy viruses, the spe-
cial DNA viruses of retroviruses, tetherin of human,
simian, bovine or canine origin inhibits the production
of infectious PFV, and similar to HIV-1, the inhibition
o fh u m a nt e t h e r i nt oP F Vi sc o u n t e r a c t e db yH I V - 1
Vpu. We also find that both the transmembrane domain
and the GPI anchor of tetherin, but not dimerization
and glycosylation, are essential for the inhibition of PFV.
These results suggest that the major structural features
of tetherin, the two membrane anchors are essential for
its antiviral activity. As the dimerization deficient
mutants still exhibit potent inhibition effect on PFV
production, our study supports a mechanism that one
pair of membrane anchors of tetherin dimer are incor-
porated into virus, and the other pair remain in cell
membrane to bridge the viruses and cells.
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